



Wednesday, October 31, 2018

CHANG YUNG-FA FOUNDATION International Convention Center

09:00-10:40	Invited Lecture	R 1001
<p>09:00-09:20</p> <p>"Proposal of absolute biologic effectiveness (ABE) dose for boron neutron capture therapy (BNCT)</p> <p>-The effect of $^{10}\text{B}(n,\alpha)^7\text{Li}$ dose can be predicted by nucleo-cytoplasmic ratio or cell size "</p> <p>Koji Ono, Osaka Medical College / Kansai BNCT Medical Center, Japan</p>		
<p>09:20-09:40</p> <p>Neutron source for neutron capture therapy</p> <p>Hiroaki Kumada, University of Tsukuba, Faculty of Medicine, Japan</p>		
<p>09:40-10:00</p> <p>BNCT Combined with Nuclear Medicine Theranostics with Astatine-211</p> <p>Jun Hatazawa, Osaka University Graduate School of Medicine/ Department of Nuclear Medicine and Tracer Kinetics, Japan</p>		
<p>10:00-10:20</p> <p>Salvage BNCT is an effective treatment option for recurrent high grade gliomas</p> <p>Yi-Wei Chen, Department of Oncology , Taipei Veterans General Hospital, Taiwan</p>		
<p>10:20-10:40</p> <p>Boron neutron capture therapy combined with early successive bevacizumab treatments for recurrent malignant gliomas</p> <p>Shin-Ichi Miyatake, Osaka Medical College/Cancer Center, Japan</p>		
10:40-11:00	Coffee Break	R 1010
11:00-11:50	Plenary Lecture	R 1001
<p>11:00-11:15</p> <p>Fundamental and pioneering achievements in basic and clinical study for BNCT</p> <p>Hiroshi Fukuda, Tohoku Medical and Pharmaceutical University/ Radiology, Japan</p>		
<p>11:15-11:30</p> <p>Treatment outcome of recurrent meningioma, diffuse intrinsic pontine glioma, recurrent extracranial rhabdomyosarcoma, and recurrent inverted papilloma</p> <p>Yuan-Hung Wu, Taipei Veterans General Hospital/ Oncology, Taiwan</p>		
<p>11:30-11:45</p> <p>Initial experience of using a hybrid PET/MRI scanner for FBPA-PET</p> <p>Ko-Han Lin, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taiwan</p>		



12:10-18:00	Technical Tour to THOR	
18:30-21:00	Congress Banquet	